Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

Incyte Pharma is nearing a deal worth up to $2 billion to acquire blood disorder drug developer Star Therapeutics, according to the Financial Times. The reported transaction would expand Incyte’s biotech pipeline and underscores continued M&A activity in healthcare. The news is constructive for both companies, with the biggest potential market impact likely limited to the involved names.

Analysis

Incyte Pharma is nearing a deal worth up to $2 billion to acquire blood disorder drug developer Star Therapeutics, according to the Financial Times. The reported transaction would expand Incyte’s biotech pipeline and underscores continued M&A activity in healthcare. The news is constructive for both companies, with the biggest potential market impact likely limited to the involved names.